Seema A Bhat (Seema Bhat)

Publication Activity (10 Years)

Years Active: 2022-2023
Publications (10 Years): 3

Top Topics

Randomized Controlled Trial

Mesenchymal Stem Cells

Tyrosine Kinase

Chronic Lymphocytic Leukemia

Top Venues

Clinical cancer research : an official journal of the American Association for Cancer Research

Cancer discovery

This page only lists publications with an associated author ORCID identifier.

Publications

Jennifer A Woyach, Deborah M Stephens, Ian W Flinn, Seema A Bhat, Ronald E Savage, Feng Chai, Sudharshan Eathiraj, Sean D Reiff, Elizabeth M Muhowski, Lindsey Granlund, Lyndsey Szuszkiewicz, Wayne Wang, Brian Schwartz, Razi Ghori, Mohammed Z H Farooqui, John C Byrd
First in Human Study of the Reversible BTK Inhibitor Nemtabrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma. Cancer discovery (2023)
Deborah M Stephens, Ying Huang, Amy S Ruppert, Janek S Walker, Daniel Canfield, Casey B Cempre, Qiang Fu, Sharyn D Baker, Boyu Hu, Harsh Shah, Renee Vadeboncoeur, Kerry A Rogers, Seema A Bhat, Samantha M Jaglowski, Hank Lockman, Rosa Lapalombella, John C Byrd, Jennifer A Woyach
Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (15) (2022)
Jonathan Mitry Hyak, Ying Huang, Kerry A Rogers, Seema A Bhat, Michael R Grever, John C Byrd, Adam S Kittai, Daniel M Jones, Cecelia R Miller, Jennifer A Woyach
Combined BCL2 and BTK inhibition in CLL demonstrates efficacy after monotherapy with both classes. Blood advances 6 (17) (2022)